The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Open accessAbstract
Venous thromboembolism (VTE) is a serious medical condition associated with significant morbidity and mortality, and an incidence that is expected to double in the next forty years. The advent of direct oral anticoagulants (DOACs) has catalyzed significant changes in the therapeutic landscape of VTE treatment. As such, it is imperative that clinicians become familiar with and appropriately implement new treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance for VTE treatment with the DOACs. When possible, guidance statements are supported by existing published evidence and guidelines. In instances where evidence or guidelines are lacking, guidance statements represent the consensus opinion of all authors of this manuscript and are endorsed by the Board of Directors of the Anticoagulation Forum.The authors of this manuscript first developed a list of pivotal practical questions related to real-world clinical scenarios involving the use of DOACs for VTE treatment. We then performed a PubMed search for topics and key words including, but not limited to, apixaban, antidote, bridging, cancer, care transitions, dabigatran, direct oral anticoagulant, deep vein thrombosis, edoxaban, interactions, measurement, perioperative, pregnancy, pulmonary embolism, reversal, rivaroxaban, switching, \thrombophilia, venous thromboembolism, and warfarin to answer these questions. Non- English publications and publications > 10 years old were excluded. In an effort to provide practical information about the use of DOACs for VTE treatment, answers to each question are provided in the form of guidance statements, with the intent of high utility and applicability for frontline clinicians across a multitude of care settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869 · cited 1×
“In clinical trials of edoxaban and dabigatran [6, 10] initial treatment consisted of open-label parenteral anticoagulation (median of 9 and 7 days in the dabigatran and edoxaban trials, respectively) overlapped with warfarin titrated to an INR of 2–3 in the control arm or overlapped with warfarin-placebo titrated to a…”
MethodPerioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Horlocker, T. T., Wedel, D. J., Rowlingson, J. C., Enneking, F. K., Kopp, S. L., Benzon, H. T., Brown, D. L., Heit, J. A., Mulroy, M. F., Rosenquist, R. W., et al. (2010) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0b013e3181c15c70 · Cited by 1,501
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366 · cited 1×
“In clinical trials of apixaban [5] and rivaroxaban [4, 8], a single-drug approach was employed without parenteral anticoagulation.”
BackgroundEerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Jiménez, D. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.199 · Cited by 1,354
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,167
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923 · cited 2×
“In VTE treatment trials, dyspepsia and gastrointestinal (GI) bleeding were more common in patients taking dabigatran as compared to warfarin or placebo [6, 7].”
BackgroundMeyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., & Farge, D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1729 · Cited by 796
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 701
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006221 · Cited by 677
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Lee, A. Y. Y., Kamphuisen, P. W., Meyer, G., Bauersachs, R., Janas, M. S., Jarner, M. F., Khorana, A. A., & for the CATCH Investigators (2015) · JAMA · doi:10.1001/jama.2015.9243 · Cited by 614
Hull, R. D., Pineo, G. F., Brant, R. F., Mah, A. F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M.-C., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.022 · Cited by 607
Healey, J. S., Eikelboom, J., Douketis, J., Wallentin, L., Oldgren, J., Yang, S., Themeles, E., Heidbuchel, H., Avezum, A., Reilly, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.090464 · Cited by 541
van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12485 · Cited by 536
Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J., & Pernod, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0179 · Cited by 501
Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures
Baron, T. H., Kamath, P. S., & McBane, R. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206531 · Cited by 457
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Self-citationvan Dongen, C. J., van den Belt, A. G., Prins, M. H., & Lensing, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub2 · Cited by 433
Factors at Admission Associated With Bleeding Risk in Medical Patients
Decousus, H., Tapson, V. F., Bergmann, J.-F., Chong, B. H., Froehlich, J. B., Kakkar, A. K., Merli, G. J., Monreal, M., Nakamura, M., Pavanello, R., et al. (2011) · Chest · doi:10.1378/chest.09-3081 · Cited by 431
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Ansell, J. E., Bakhru, S. H., Laulicht, B. E., Steiner, S. S., Grosso, M., Brown, K., Dishy, V., Noveck, R. J., & Costin, J. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1411800 · Cited by 419
Self-citationHibbard, J. H., Greene, J., & Overton, V. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1064 · Cited by 398
Deitcher, S. R., Kessler, C. M., Merli, G., Rigas, J. R., Lyons, R. M., & Fareed, J. (2006) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029606293692 · Cited by 392
How I treat anticoagulated patients undergoing an elective procedure or surgery
Spyropoulos, A. C., & Douketis, J. D. (2012) · Blood · doi:10.1182/blood-2012-06-415943 · Cited by 375
Mueck, W., Kubitza, D., & Becka, M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12075 · Cited by 371
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
Kaatz, S., Kouides, P. A., Garcia, D. A., Spyropolous, A. C., Crowther, M., Douketis, J. D., Chan, A. K. C., James, A., Moll, S., Ortel, T. L., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23202 · Cited by 365
Self-citationThe P-Glycoprotein Transport System and Cardiovascular Drugs
Wessler, J. D., Grip, L. T., Mendell, J., & Giugliano, R. P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.058 · Cited by 362
Dabigatran Etexilate: A New Oral Thrombin Inhibitor
Hankey, G. J., & Eikelboom, J. W. (2011) · Circulation · doi:10.1161/circulationaha.110.004424 · Cited by 348
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
Hylek, E. M., Held, C., Alexander, J. H., Lopes, R. D., De Caterina, R., Wojdyla, D. M., Huber, K., Jansky, P., Steg, P. G., Hanna, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.549 · Cited by 344
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
Chai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Marchesi, C., Pierfranceschi, M., Crowther, M., Garcia, D., Hylek, E., Witt, D., Clark, N., Squizzato, A., Imberti, D., Ageno, W., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0052 · Cited by 306
Self-citationLIESENFELD, K. ‐., LEHR, T., DANSIRIKUL, C., REILLY, P. A., CONNOLLY, S. J., EZEKOWITZ, M. D., YUSUF, S., WALLENTIN, L., HAERTTER, S., & STAAB, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04498.x · Cited by 305
Erkens, P. M., & Prins, M. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub3 · Cited by 301
Bleeding Risk with Dabigatran in the Frail Elderly
Harper, P., Young, L., & Merriman, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1112874 · Cited by 285
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277
Direct Oral Anticoagulants in Patients With VTE and Cancer
Vedovati, M. C., Germini, F., Agnelli, G., & Becattini, C. (2015) · Chest · doi:10.1378/chest.14-0402 · Cited by 270
Upreti, V. V., Wang, J., Barrett, Y. C., Byon, W., Boyd, R. A., Pursley, J., LaCreta, F. P., & Frost, C. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12114 · Cited by 269
Sherwood, M. W., Douketis, J. D., Patel, M. R., Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., Spyropoulos, A. C., Hankey, G. J., Singer, D. E., Nessel, C. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005754 · Cited by 267
Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C. A., Maxwell, B. D., Chen, S.-Y., He, K., Goosen, T. C., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029694 · Cited by 253
Zahir, H., Brown, K. S., Vandell, A. G., Desai, M., Maa, J.-F., Dishy, V., Lomeli, B., Feussner, A., Feng, W., He, L., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013445 · Cited by 252
Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A.-M., Emmerich, J., Marchand-Leroux, C., Lecompte, T., & Samama, C.-M. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318238c036 · Cited by 246
Johnson, A., Sandford, J., & Tyndall, J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003716 · Cited by 244
Pros and cons of new oral anticoagulants
Bauer, K. A. (2013) · Hematology · doi:10.1182/asheducation-2013.1.464 · Cited by 226
Mendell, J., Zahir, H., Matsushima, N., Noveck, R., Lee, F., Chen, S., Zhang, G., & Shi, M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0029-0 · Cited by 223
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Gnoth, M. J., Buetehorn, U., Muenster, U., Schwarz, T., & Sandmann, S. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180240 · Cited by 216
Gong, I. Y., & Kim, R. B. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.002 · Cited by 201
PRAGST, I., ZEITLER, S. H., DOERR, B., KASPEREIT, F. J., HERZOG, E., DICKNEITE, G., & van RYN, J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04859.x · Cited by 186
Piccini, J. P., Garg, J., Patel, M. R., Lokhnygina, Y., Goodman, S. G., Becker, R. C., Berkowitz, S. D., Breithardt, G., Hacke, W., Halperin, J. L., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu083 · Cited by 170
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures
Garcia, D., Alexander, J. H., Wallentin, L., Wojdyla, D. M., Thomas, L., Hanna, M., Al-Khatib, S. M., Dorian, P., Ansell, J., Commerford, P., et al. (2014) · Blood · doi:10.1182/blood-2014-08-595496 · Cited by 169
Self-citationvan der Hulle, T., den Exter, P. L., Kooiman, J., van der Hoeven, J. J. M., Huisman, M. V., & Klok, F. A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12605 · Cited by 164
Davidson, B. L., Verheijen, S., Lensing, A. W. A., Gebel, M., Brighton, T., Lyons, R. M., Rehm, J., & Prins, M. H. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.946 · Cited by 146
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates
Gruber, A., Tinel, H., Marzec, U. M., Buetehorn, U., Buchmüller, A., Heitmeier, S., Laux, V., & Perzborn, E. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0907 · Cited by 125
How I treat target-specific oral anticoagulant–associated bleeding
Siegal, D. M., Garcia, D. A., & Crowther, M. A. (2014) · Blood · doi:10.1182/blood-2013-09-529784 · Cited by 121
Self-citationDecrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin
Härtter, S., Koenen‐Bergmann, M., Sharma, A., Nehmiz, G., Lemke, U., Timmer, W., & Reilly, P. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04218.x · Cited by 120
Coagulation assays and anticoagulant monitoring
Funk, D. M. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.460.3798662 · Cited by 111
Martin, A., Bonniec, B. L., Fischer, A., Marchand‐Leroux, C., Gaussem, P., Samama, C. M., & Godiér, A. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.152 · Cited by 99
Schaefer, J. K., McBane, R. D., Black, D. M., Williams, L. N., Moder, K. G., & Wysokiński, W. E. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0272 · Cited by 93
Mantha, S. H., & Ansell, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1102-5 · Cited by 92
Self-citationDager, W. E., Gosselin, R. C., & Roberts, A. J. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827caaa3 · Cited by 90
FDA drug safety communications: a narrative review and clinical considerations for older adults
Marcum, Z. A., Vande Griend, J. P., & Linnebur, S. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.05.002 · Cited by 85
Transfer of Dabigatran and Dabigatran Etexilate Mesylate Across the Dually Perfused Human Placenta
Bapat, P., Kedar, R., Lubetsky, A., Matlow, J. N., Aleksa, K., Berger, H. M., & Koren, G. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000277 · Cited by 80
Delavenne, X., Ollier, É., Basset, T., Bertoletti, L., Accassat, S., Garcin, A., Laporte, S., Zufferey, P. J., & Mismetti, P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12055 · Cited by 71
The Top 100 Drug Interactions: A Guide to Patient Management
Carpenter, J. F. (2002) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr2002324294 · Cited by 69
New oral anticoagulant agents – general features and outcomes in subsets of patients
Schulman, S. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0803 · Cited by 67
Win, K. Z., & Rodgers, G. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23797 · Cited by 64
Larsen, T. B., Nielsen, P. B., Skjøth, F., Rasmussen, L. H., & Lip, G. Y. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114445 · Cited by 64
New oral anticoagulants: which one should my patient use?
Weitz, J. I., & Gross, P. L. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.536.3798545 · Cited by 49
New Oral Anticoagulants in Patients With Cancer: Current State of Evidence
Sardar, P., Chatterjee, S., Herzog, E., Pekler, G., Mushiyev, S., Pastori, L. J., Visco, F., & Aronow, W. S. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000055 · Cited by 34
Sipahi, İ., Çelık, S., & Tozun, N. A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12217 · Cited by 32
Reversal of target-specific oral anticoagulants
Siegal, D. M., & Cuker, A. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.013 · Cited by 32
Transitions of care in anticoagulated patients
Michota, F. A. (2013) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s44068 · Cited by 29
The newer direct oral anticoagulants: a practical guide
Thachil, J. V. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-2-165 · Cited by 25
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Ageno, W., Crowther, M. A., Baglin, T. P., Falanga, A., Buller, H. R., & Palareti, G. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12038 · Cited by 22
Stöllberger, C., & Finsterer, J. (2014) · Heart & Lung · doi:10.1016/j.hrtlng.2014.03.004 · Cited by 19
Treating Acute Venous Thromboembolism — Shift with Care
Cushman, M. (2013) · New England Journal of Medicine · doi:10.1056/nejme1307413 · Cited by 15
Spyropoulos, A. C., Viscusi, A., Singhal, N., Gilleylen, J., Kouides, P. A., Howard, M., Rudd, K. M., Ansell, J., & Triller, D. M. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014555176 · Cited by 15
Self-citationAntithrombotic Medication Use and Bleeding Risk in Medically Ill Patients After Hospitalization
Mahan, C. E., Spyropoulos, A. C., Fisher, M. D., Fields, L. E., Mills, R. M., Stephenson, J. J., Fu, A.-C., & Klaskala, W. I. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612470967 · Cited by 14
Self-citationStroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction
Kaatz, S., & Mahan, C. E. (2014) · Stroke · doi:10.1161/strokeaha.114.005117 · Cited by 14
Self-citationTransitioning to and from the novel oral anticoagulants: a management strategy for clinicians
Abo‐Salem, E., & Becker, R. C. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1060-y · Cited by 12
Cited by
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cífková, R., De Bonis, M., Iung, B., Johnson, M. R., Kintscher, U., Kranke, P., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy340 · Cited by 2,292
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Patel, I. J., Rahim, S., Davidson, J. C., Hanks, S. E., Tam, A. L., Walker, T. G., Wilkins, L. R., Sarode, R., & Weinberg, I. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2019.04.017 · Cited by 610
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Martin, K., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13323 · Cited by 445
Metadata
- Authors
- Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J.
- Venue
- Journal of Thrombosis and Thrombolysis
- Published
- 2016-01
- Volume
- 41
- Issue
- 1
- Pages
- 206-232
- ISSN
- 0929-5305 (ISSN-L)
- 1573-742X
- OpenAlex
- W2291575320
- Cited by
- 333
- References
- 101
- FWCI
- 41.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.